← Home / Hormonal / Mary Claire Haver / Hormone Therapy and Heart Risk: Does Timing Matter?
HormonalHormonesHeartLongevityBeginner Menopause & Perimenopause

Hormone Therapy and Heart Risk: Does Timing Matter?

Updated July 10, 2026

Whether hormone therapy helps or hurts your heart may depend heavily on when you start it. In the Women’s Health Initiative, women who began hormone therapy nearer to menopause (their 50s) trended toward lower heart-disease risk in that data, while women who started a decade or more later (their 70s) trended toward higher risk. This is informational, not a recommendation; the decision belongs with your own clinician.

🌟
Mary Claire Haver
The Pause Life
Not endorsed · Based on the published work of Mary Claire Haver
Daily time
6 min
Steps
4
Difficulty
Beginner
Sources
3
View the steps →
What it is

Whether hormone therapy helps or hurts your heart may depend heavily on when you start it. This page walks through the age-stratified evidence; informational only, the decision belongs with your own clinician.

Why it works▼
In the Women’s Health Initiative, age at the start of hormone therapy was linked to markedly different cardiovascular outcomes: lower heart-disease risk for women who started nearer to menopause (their 50s), versus higher risk for those who started a decade or more later (their 70s). The ELITE trial then tested timing directly with randomization and found estradiol slowed artery-wall thickening in women under 6 years past menopause, with no effect in women 10 or more years out. Dr. Haver frames the group most likely to see benefit outweigh risk as roughly under 60 and within about 10 years of menopause: a framework for the conversation with your clinician, not a personalized prescription.
The evidence
Sources
Published work by Mary Claire Haver, cited straight to the source: long-form episodes, clips, peer-reviewed papers and their own writing. Select any to view it here.
1
Is Hormone Therapy After 60 Still on the Table? (Dr. Mary Claire Haver)
Article
2
Your Heart on Menopause (Dr. Mary Claire Haver)
Article
3
Hodis et al. - Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE, NEJM 2016)
Paper
Source viewer
Loading the first source…
The protocol
Clinical strong human trials Mixed some or emerging evidence Commercial weak or unproven, sold widely Equipment / Test not an evidence claim How we grade →
Know the age-stratified WHI finding

Look at the age-stratified data first

Starting near menopause looked protective for the heart; starting a decade or more later did not

Age at initiation appears to change the entire risk-benefit picture for cardiovascular outcomes.

WHI age-stratified analysis
For this step
No product needed
Know the trial built to test timing directly

Consider the randomized evidence, not just observational data

The ELITE trial randomized women by time since menopause and found estradiol slowed artery-wall thickening in women under 6 years post-menopause, with no effect in women 10+ years out

ELITE was designed specifically to test the timing hypothesis with randomization, which strengthens confidence in the age-related pattern.

Hodis et al., NEJM 2016 (ELITE)
For this step
No product needed
Understand the 'window of opportunity' framing

Use this as a framework, not a rule

Haver describes the group most likely to see benefit outweigh risk as roughly under 60 and within about 10 years of menopause

This framing helps organize the conversation with your clinician, but it is a guideline, not an individual guarantee.

Haver - Is Hormone Therapy After 60 Still on the Table?
For this step
No product needed
What to actually do

Have the conversation with your clinician

Bring your age, years since menopause, and personal and family cardiovascular history to your OB-GYN or a menopause-trained clinician; this is an individual risk-benefit conversation and this page gives no doses

This is an individualized risk-benefit decision that depends on your personal history, and this page intentionally gives no doses.

WHI age-stratified analysis / Hodis et al., NEJM 2016
For this step
No product needed
Is this for you?
Good fit if
  • Women considering hormone therapy near menopause
  • Women wondering if it's 'too late' to start hormone therapy
  • Anyone who wants the age-stratified evidence before talking to their doctor
  • People weighing personal or family cardiovascular history against menopause symptoms
Cautions
  • This is an individual decision that belongs with your own clinician; this page gives no doses
  • The WHI age-stratification was a subgroup analysis, not the trial’s original primary design, an important caveat on how strongly it should be weighted
  • A history of hormone-sensitive cancer changes the calculus entirely and should be discussed directly with your clinician
  • Educational only, not medical advice
Common questions
Does starting hormone therapy earlier make it safer for the heart?▾
The evidence suggests timing matters. In the Women’s Health Initiative, women who started nearer to menopause (their 50s) trended toward lower heart-disease risk, while women who started a decade or more later (their 70s) trended toward higher risk. This is informational, not a personal recommendation.
What is the 'window of opportunity'?▾
It’s the idea, discussed by Dr. Haver, that the group most likely to see benefit outweigh risk is roughly women under 60 and within about 10 years of menopause. It is a framework for discussion with your clinician, not a rule.
Was the WHI age analysis part of the original trial design?▾
No. The age-stratified finding was a subgroup analysis of the WHI, not the trial’s original primary design, an important caveat on how strongly it should be weighted.
What did the ELITE trial add?▾
ELITE randomized women by time since menopause and found estradiol slowed artery-wall thickening in women under 6 years post-menopause, with no effect in women 10 or more years out, supporting the timing idea with a randomized design (Hodis et al., NEJM 2016).
Does this page tell me what dose to take?▾
No. This page is educational only. Hormone therapy type, dose, and timing are individual decisions that belong with your OB-GYN or a menopause-trained clinician, especially given personal and family cardiovascular and cancer history.
Related protocols
🌟
Hormonal
Menopause Strength & Metabolic Reset
Based on the work of Mary Claire Haver
🥗
Nutrition
The Galveston Diet
Based on the work of Mary Claire Haver
Update history
  • July 10, 2026 Protocol published.
Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol.ai is an independent platform. This protocol is based on the publicly available work of Mary Claire Haver and is not created, reviewed, endorsed by, or affiliated with Mary Claire Haver or The Pause Life.

Hormone Therapy and Heart Risk: Does Timing Matter?
Follow the steps
View steps